Skip to main content
. 2013 Oct 23;33(43):17023–17028. doi: 10.1523/JNEUROSCI.2124-13.2013

Figure 1.

Figure 1.

Interaction between reboxetine and ADRA2B genotype influences post-treatment symptoms of irritability, anxiety, and dizziness. A, Significant decrease in post-treatment irritability in ADRA2B deletion carriers under placebo that was absent in nondeletion carriers. B, Significant decrease in anxiety in ADRA2B deletion carriers under placebo compared with reboxetine. C, Significant increase in dizziness in ADRA2B nondeletion carriers under reboxetine compared with placebo. *p < 0.05. **p < 0.01. ***p < 0.001. Bars indicate SEM.